Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED

/PRNewswire/ --The EspeRare Foundation and the Pierre Fabre group announced today that the first patient in the EDELIFE clinical trial has received the three...

Related Keywords

Erlangen ,Bayern ,Germany ,United States ,United Kingdom ,Italy ,Vigolo ,Veneto ,Switzerland ,France ,Spain ,Italian ,French ,Spanish ,British ,German ,Swiss ,Schneider Pn Engl ,Pierre Fabre ,Holm Schneider ,Caroline Kant ,Deborah Szafir ,J Clin Pharmacol ,Esperare Foundation ,University Hospital Erlangen ,Patient Consumer Division At Pierre Fabre ,Nature Medicine Research ,Us Federal Drug Administration ,Pierre Fabre Foundation ,European Medical Agency Ema Prime Priority Medicines ,Hypohidrotic Ectodermal Dysplasia ,Executive Vice President ,Patient Consumer Division ,Breakthrough Therapy Designation ,Drug Administration ,European Medical Agency ,New England Journal ,British Journal ,Nature Medicine ,Pierre Fabre Oncology ,Pierre Fabre Dermatology ,Pierre Fabre Oral ,X Linked Hypohidrotic Ectodermal ,Englj Med ,